Genome-wide tracts of homozygosity and exome analyses reveal repetitive elements with Barrets esophagus/esophageal adenocarcinoma risk.
Barrett’s esophagus
Esophageal adenocarcinoma
Exome
Omics
Tracts of homozygosity
Journal
BMC bioinformatics
ISSN: 1471-2105
Titre abrégé: BMC Bioinformatics
Pays: England
ID NLM: 100965194
Informations de publication
Date de publication:
14 Mar 2019
14 Mar 2019
Historique:
entrez:
16
3
2019
pubmed:
16
3
2019
medline:
3
5
2019
Statut:
epublish
Résumé
Barrett's esophagus (BE) is most commonly seen as the condition in which the normal squamous epithelium lining of the esophagus is replaced by goblet cells. Many studies show that BE is a predisposing factor for the development of esophageal adenocarcinoma (EAC), a particularly lethal cancer. The use of single nucleotide polymorphisms (SNPs) to map BE/EAC genes has previously provided insufficient genetic information to fully characterize the heterogeneous nature of the disease. We therefore hypothesize that rigorous interrogation of other types of genomic changes, e.g. tracts of homozygosity (TOH), repetitive elements, and insertion/deletions, may provide a comprehensive understanding of the development of BE/EAC. First, we used a case-control framework to identify TOHs by using SNPs and tested for association with BE/EAC. Second, we used a case only approach on a validation series of eight samples subjected to exome sequencing to identify repeat elements and insertion/deletions. Third, insertion/deletions and repeat elements identified in the exomes were then mapped onto genes in the significant TOH regions. Overall, 24 TOH regions were significantly differentially represented among cases, as compared to controls (adjusted-P = 0.002-0.039). Interestingly, four BE/EAC-associated genes within the TOH regions consistently showed insertions and deletions that overlapped across eight exomes. Predictive functional analysis identified NOTCH, WNT, and G-protein inflammation pathways that affect BE and EAC. The integration of common TOHs (cTOHs) with repetitive elements, insertions, and deletions within exomes can help functionally prioritize factors contributing to low to moderate penetrance predisposition to BE/EAC.
Sections du résumé
BACKGROUND
BACKGROUND
Barrett's esophagus (BE) is most commonly seen as the condition in which the normal squamous epithelium lining of the esophagus is replaced by goblet cells. Many studies show that BE is a predisposing factor for the development of esophageal adenocarcinoma (EAC), a particularly lethal cancer. The use of single nucleotide polymorphisms (SNPs) to map BE/EAC genes has previously provided insufficient genetic information to fully characterize the heterogeneous nature of the disease. We therefore hypothesize that rigorous interrogation of other types of genomic changes, e.g. tracts of homozygosity (TOH), repetitive elements, and insertion/deletions, may provide a comprehensive understanding of the development of BE/EAC.
RESULTS
RESULTS
First, we used a case-control framework to identify TOHs by using SNPs and tested for association with BE/EAC. Second, we used a case only approach on a validation series of eight samples subjected to exome sequencing to identify repeat elements and insertion/deletions. Third, insertion/deletions and repeat elements identified in the exomes were then mapped onto genes in the significant TOH regions. Overall, 24 TOH regions were significantly differentially represented among cases, as compared to controls (adjusted-P = 0.002-0.039). Interestingly, four BE/EAC-associated genes within the TOH regions consistently showed insertions and deletions that overlapped across eight exomes. Predictive functional analysis identified NOTCH, WNT, and G-protein inflammation pathways that affect BE and EAC.
CONCLUSIONS
CONCLUSIONS
The integration of common TOHs (cTOHs) with repetitive elements, insertions, and deletions within exomes can help functionally prioritize factors contributing to low to moderate penetrance predisposition to BE/EAC.
Identifiants
pubmed: 30871476
doi: 10.1186/s12859-019-2622-y
pii: 10.1186/s12859-019-2622-y
pmc: PMC6419328
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
98Références
Biochem Cell Biol. 2005 Jun;83(3):296-321
pubmed: 15959557
Int J Cancer. 1998 Sep 11;77(6):833-8
pubmed: 9714050
Nat Genet. 2017 Jul;49(7):986-992
pubmed: 28530675
Am J Hum Genet. 2007 Sep;81(3):559-75
pubmed: 17701901
Lab Invest. 2012 Jun;92(6):896-909
pubmed: 22449796
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
Nat Genet. 2013 May;45(5):478-86
pubmed: 23525077
Cancer Sci. 2010 Mar;101(3):624-30
pubmed: 20128822
Cancer Res. 2016 Oct 1;76(19):5628-5633
pubmed: 27503924
Science. 2011 Feb 4;331(6017):593-6
pubmed: 21233348
Cell Rep. 2015 Mar 17;10(10):1674-1680
pubmed: 25772355
Cancer Res. 2008 Apr 15;68(8):2610-21
pubmed: 18375840
Mutat Res. 1999 Jan 25;423(1-2):91-101
pubmed: 10029684
Hum Hered. 2015;79(1):14-9
pubmed: 25720536
JAMA. 2011 Jul 27;306(4):410-9
pubmed: 21791690
Nat Rev Genet. 2018 May;19(5):286-298
pubmed: 29398703
Genome Res. 2004 Oct;14(10A):1861-9
pubmed: 15466286
Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19942-7
pubmed: 18077426
Stem Cells. 2011 Apr;29(4):678-88
pubmed: 21308863
Oncogene. 2002 Aug 12;21(35):5400-13
pubmed: 12154403
Hum Mol Genet. 2006 Mar 1;15(5):789-95
pubmed: 16436455
Nat Commun. 2017 Sep 12;8(1):524
pubmed: 28900112
Genet Med. 2015 May;17(5):396-9
pubmed: 25232855
Clin Gastroenterol Hepatol. 2014 Oct;12(10):1664-6
pubmed: 24657839
Epigenomics. 2010 Apr;2(2):245-69
pubmed: 22121873
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Cytogenet Genome Res. 2005;110(1-4):462-7
pubmed: 16093699
Cancer Genet Cytogenet. 1999 Feb;109(1):34-9
pubmed: 9973957
Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):18946-51
pubmed: 24158479
PLoS One. 2013 Jun 07;8(6):e66133
pubmed: 23762476
Nat Rev Genet. 2006 Feb;7(2):85-97
pubmed: 16418744
Cancer Res. 2011 Oct 1;71(19):6106-15
pubmed: 21844183
Nucleic Acids Res. 2005 Dec 02;33(21):6823-36
pubmed: 16326863
J Biol Chem. 2006 Sep 8;281(36):26483-90
pubmed: 16787920
Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):18748-9
pubmed: 24191054
Oncogene. 2006 Apr 27;25(18):2636-45
pubmed: 16532039
PLoS One. 2012;7(1):e30181
pubmed: 22291914
Mod Pathol. 2009 Mar;22(3):442-9
pubmed: 19136926
Biochem Biophys Res Commun. 2016 May 13;473(4):1240-1246
pubmed: 27084452
Nat Genet. 2008 May;40(5):491-2
pubmed: 18443580
PLoS One. 2017 Oct 26;12(10):e0184962
pubmed: 29073141
Hum Hered. 2014;77(1-4):63-72
pubmed: 25060270
Mol Biol Evol. 2000 Aug;17(8):1268-75
pubmed: 10908647
Recent Prog Horm Res. 2003;58:283-95
pubmed: 12795424
Gastrointest Tumors. 2016 Oct;3(2):103-108
pubmed: 27904862
Am J Hum Genet. 1988 Oct;43(4):520-6
pubmed: 3177389
Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1668-73
pubmed: 16985029
Genetics. 2003 Aug;164(4):1279-89
pubmed: 12930739
Nat Genet. 2006 Aug;38(8):904-9
pubmed: 16862161
Nat Rev Genet. 2011 Nov 29;13(1):36-46
pubmed: 22124482
Proc Natl Acad Sci U S A. 2006 May 23;103(21):8173-8
pubmed: 16705036
PLoS One. 2010 Nov 15;5(11):e13996
pubmed: 21085596
Cancer Genomics Proteomics. 2016 May-Jun;13(3):231-8
pubmed: 27107065
PLoS One. 2012;7(2):e31975
pubmed: 22384118
Mol Cancer Res. 2003 Aug;1(10):729-38
pubmed: 12939398
Lancet Oncol. 2016 Oct;17(10):1363-1373
pubmed: 27527254
Nat Genet. 1994 Feb;6(2):152-6
pubmed: 8162069
Therap Adv Gastroenterol. 2010 Jul;3(4):227-38
pubmed: 21180605
Br J Cancer. 2004 Aug 31;91(5):985-94
pubmed: 15292941
Genome Biol. 2008;9 Suppl 1:S4
pubmed: 18613948
J Cell Commun Signal. 2016 Jun;10(2):129-35
pubmed: 27041549
Nucleic Acids Res. 2008 Feb;36(3):770-84
pubmed: 18084025
Cell Cycle. 2014;13(24):3857-66
pubmed: 25558829
Brief Bioinform. 2013 Mar;14(2):178-92
pubmed: 22517427
Genome Biol Evol. 2018 Mar 1;10(3):918-927
pubmed: 29608719
Epigenetics. 2017 Jul 3;12(7):515-526
pubmed: 28426282
Gastroenterol Rep (Oxf). 2015 Nov;3(4):303-15
pubmed: 26486568